Clinical Trial Update: Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating neoadjuvant adebrelimab plus etoposide and cisplatin for neuroendocrine carcinoma of the bladder, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Neuroendocrine Carcinoma of the Bladder

Drugs mentioned

• Adebrelimab (adebrelimab)
• CISPLATIN (cisplatin)
• Etoposide (Etoposide)

Snippet

Sponsor: RenJi Hospital | Conditions: Neuroendocrine Carcinoma of the Bladder, Bladder Cancer | Phase 2 | Status: RECRUITING